US: ASCLF - Ascletis Pharma Inc

Yield per half year: +258.09%
Dividend yield: 0.00%

Share chart Ascletis Pharma Inc

Extended chart Simple chart
Financial Markets by TradingView

About Ascletis Pharma Inc

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.

more details
In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cny
Сайт https://www.ascletis.com
Цена ао 1.2
Change price per day: +0.0483% (0.6217)
Change price per week: +0.0483% (0.6217)
Change price per month: -40.42% (1.0439)
Change price per 3 month: +159.92% (0.2393)
Change price per half year: +258.09% (0.1737)
Change price per year: +207.46% (0.2023)
Change price per 3 year: +38.13% (0.4503)
Change price per 5 year: -4.31% (0.65)
Change price per year to date: +159.92% (0.2393)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -67.37 0
Yield Ebitda, % 782.25 10
Yield EPS, % 913.01 10
Total: 6.8
More

Head Job title Payment Year of birth
Dr. Jinzi Jason Wu Ph.D. Founder, Chairman & CEO 1964 (61 year)
Ms. Hejingdao Wu Senior VP of Operations & Executive Director 1974 (51 year)
Ms. Yuemei Yan Senior Vice President of Clinical Development Operations 1970 (55 years)
Dr. Kristjan Sigurdur Gudmundsson Senior Consultant & Head of Discovery 1968 (57 years)
Dr. George Zhengzhi Hill Senior Consultant & Chief Medical Advisor 1951 (74 years)
Mr. John P. Gargiulo M.B.A. Chief Business Officer 1960 (65 years)
Mr. Ming Fai Chung CPA Company Secretary 1979 (46 years)

Address: China, Hangzhou, Building D - open in Google maps, open in Yandex maps
Website: https://www.ascletis.com